Reported Standalone quarterly numbers for Ajanta Pharma are:Net Sales at Rs 560.85 crore in June 2020 up 2.77% from Rs. 545.74 crore in June 2019.
Quarterly Net Profit at Rs. 115.69 crore in June 2020 down 6.4% from Rs. 123.60 crore in June 2019.
EBITDA stands at Rs. 186.53 crore in June 2020 up 4.06% from Rs. 179.25 crore in June 2019.
Ajanta Pharma EPS has decreased to Rs. 13.26 in June 2020 from Rs. 14.17 in June 2019.
Ajanta Pharma shares closed at 1,512.40 on July 30, 2020 (NSE) and has given 50.64% returns over the last 6 months and 47.28% over the last 12 months.
| Ajanta Pharma | | Standalone Quarterly Results | in Rs. Cr. |
|
| Jun'20 | Mar'20 | Jun'19 | | Net Sales/Income from operations | 560.85 | 560.68 | 545.74 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 560.85 | 560.68 | 545.74 | | EXPENDITURE | | Consumption of Raw Materials | 153.32 | 172.29 | 123.79 | | Purchase of Traded Goods | 22.59 | 22.99 | 28.63 | | Increase/Decrease in Stocks | -25.53 | -24.34 | 11.07 | | Power & Fuel | -- | -- | -- | | Employees Cost | 123.82 | 117.26 | 107.37 | | Depreciation | 26.86 | 24.89 | 21.71 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 113.22 | 166.63 | 135.25 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | 146.57 | 80.96 | 117.92 | | Other Income | 13.10 | 54.10 | 39.62 | | P/L Before Int., Excpt. Items & Tax | 159.67 | 135.06 | 157.54 | | Interest | 1.20 | 2.93 | 1.09 | | P/L Before Exceptional Items & Tax | 158.47 | 132.13 | 156.45 | | Exceptional Items | -- | -2.51 | -- | | P/L Before Tax | 158.47 | 129.62 | 156.45 | | Tax | 42.78 | 41.11 | 32.85 | | P/L After Tax from Ordinary Activities | 115.69 | 88.51 | 123.60 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | 115.69 | 88.51 | 123.60 | | Equity Share Capital | 17.54 | 17.54 | 17.54 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | 13.26 | 10.14 | 14.17 | | Diluted EPS | 13.26 | 10.14 | 14.16 | | EPS After Extra Ordinary | | Basic EPS | 13.26 | 10.14 | 14.17 | | Diluted EPS | 13.26 | 10.14 | 14.16 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
First Published on Jul 31, 2020 09:33 am
